World scientists believe that a new era in the fight against dementia has begun. This happened after it was officially proven that the new drug Donanemab slows the progression of Alzheimer’s disease.
By breaking down clumps of toxic proteins that build up in the brains of patients at an early stage, the drug was able to stop the course of the disease.
The study of the drug involved 1736 people aged 60 to 85 years with early stage Alzheimer’s disease. Doctors compared the development of their disease for 18 months. People with milder symptoms were found to have excellent results from donanemab. But people in worse condition also showed improvement.
In general, those who took the test drug had an average of 35% less mental decline after six months. They were better at conversations, managing their money, or pursuing hobbies than people who weren’t given medicine.
British charity Alzheimer’s Society proclaimed the results of the study “the beginning of the end of Alzheimer’s disease».
Dr. Mark Boucher of the British Dementia Research Institute says: “Today, this therapy can dramatically improve the lives of patients and their families.”
Until now, there has been no cure or way in the world to slow down the deadly disease that robs the sick of memory and physical strength.
Now the pharmaceutical giant Eli Lilly, which conducted the research, must obtain all permits and prepare for the release of the drug.
However, the drug has a number of side effects, such as swelling and bleeding in the brain. In 24% of those who took the medicine, cerebral edema was observed. Those who received the placebo did not experience this side effect. Brain hemorrhage occurred in 31% of the participants in the trial, in the placebo group – in 13%. Three participants died of hemorrhage. Now representatives of the pharmaceutical giant will study all the risks of side effects and launch the drug on the market in 2024.
2023-05-06 08:06:30
#drug #slows #Alzheimers
